INTERNATIONAL PATENT: INCYTE CORPORATION, SYNDAX PHARMACEUTICALS, INC. FILES APPLICATION FOR "COMBINATION THERAPY WITH AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY AND A JAK INHIBITOR"

GENEVA, Nov. 5 -- INCYTE CORPORATION (1801 Augustine Cut-OffWilmington, Delaware 19803), SYNDAX PHARMACEUTICALS, INC. (35 Gatehouse Drive, Building D, Floor 3Waltham, Massachusetts 02451) filed a patent application (PCT/US2025/025703) for "COMBINATION THERAPY WITH AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY AND A JAK INHIBITOR" on Apr 22, 2025. With publication no. WO/2025/226637, the details related to the patent application was published on Oct 30, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): LANGMUIR, Peter (1801 Augustine Cut-OffWilmington, Delaware 19803), OHANNESIAN, Lena ...